Sudden hearing loss associated with tacrolimus in a kidney-pancreas allograft recipient

Pharmacotherapy

Volumn 19, Issue 7, 1999, Pages 891-893

  Min, David I ^a   Ku, Yi Min ^a   Rayhill, Stephen ^b   Corwin, Claudia ^b   Wu, You Min ^b   Hunsicker, Lawrence G ^b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; TACROLIMUS;

ADULT; ARTICLE; CASE REPORT; DRUG BLOOD LEVEL; DRUG INDUCED DISEASE; FEMALE; GRAFT REJECTION; HEARING LOSS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; PANCREAS TRANSPLANTATION;

ADULT; FEMALE; GRAFT REJECTION; HEARING LOSS, SUDDEN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; PANCREAS TRANSPLANTATION; TACROLIMUS;

EID: 0032850402     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.19.10.891.31562     Document Type: Article

References (13)

1. Goto T, Kino T, Hatanaka H, et al. Discovery of FK-506, a novel immunosuppressant isolated from a Streptomyces tsukubaensis. Transplant Proc 1987;19:4-8.
2. Tanaka H, Kuroda A, Marusawa H, et al. Physicochemical properties of FK 506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. Transplant Proc 1987;19: 11-16.
3. Kelly PA, Burckart GJ, Venkataramanan R. Tacrolimus: a new immunosuppressive agent. Am J Health-Syst Pharm 1995;52: 1521-35.
4. Gold BG. FK 506 and the role of immunophilins in nerve regeneration. Mol Neurobiol 1997;15:285-306.
5. Snyder SH, Sabatini DM, Lai MM, Steiner JP, Hamilton GS, Suzdak PD. Neural actions of immunophilin ligands. Trends Pharmacol Sci 1998;19:21-6.
6. Haydon RC, Thelin JW, David WE. Erythromycin ototoxicity: analysis and conclusions based on 22 case reports. Otolaryngol Head Neck Surg 1984;92:678-84.
7. Vasquez EM, Maddux MS, Sanchez J, Pollak R. Clinically significant hearing loss in renal allograft recipients treated with intravenous erythromycin. Arch Intern Med 1993;153:879-82.
8. Swanson DJ, Sung RJ, Fine MJ, Orloff JJ, Chu SY, Yu VL. Erythromycin ototoxicity: prospective assessment with serum concentrations and audiograms in a study of patients with pneumonia. Am J Med 1992;92:61-8.
9. Liu J, Marcus DC, Kobayashi T. Inhibitory effect of erythromycin on ion transport by stria vascularis and vestibular dark cells. Acta Otolaryngol 1996;116:572-5.
10. Kobayashi T, Rong Y, Chiba T, Marcus DC, Ohyama K, Takasaka T. Ototoxic effect of erythromycin on cochlear potentials in the guinea pig. Ann Otol Rhinol Laryngol 1997;106:599-603.
11. Sanoski CA, Vasquez EM, Bauman JL. QT interval prolongation associated with the use of tacrolimus in transplant recipients [abstr]. Pharmacotherapy 1998;18:427.
12. Novartis Co. Sandimmune (Neoral) package insert. East Hanover, NJ;1998.
13. Hartnick CJ, Cohen AF, Smith RV. Reversible sensorineural hearing loss after renal transplant immunosuppression with OKT3 (muromonab-CD3). Ann Otol Rhinol Laryngol 1997;106:640-2.